Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

logo-inverse

Bioadhesive Ophthalmics awarded as the best start-up 2021 by Neighborhood, VCLS Innovation Center and Voisin Consulting Life Sciences (VCLS)

A wonderful evening with our start-ups, partners, mentors, investors, friends from the Neighborhood community.

Congratulations to the start-ups that won the awards:
🏆 Best start-up: Bioadhesive Ophthalmics, Jean GARREC, Jean Cuiné
🏆 Innovation Award: Hemerion Therapeutics, Maximilien Vermandel, Clément DUPONT
🏆 People Award: flowbone SA, Régis Gauderon, Ulrike Kettenberger

Also, congratulations to our mentors who won the mentor awards. The start-ups made progress on their access to market and regulatory strategy together with you!
🏆 Excellence Award: Cecile Rousseau, PhD
🏆 Passion Award: Charlène Revel
🏆 Mighty Guru: François Gianelli

Thank you, our Neighborhood team: Sébastien Giraudier, PhD, Pauline Seiter, Zakaria HIJJI for organizing such a great event and our coach Alison Munro!

Related posts
acticor
admin

Acticor Biotech obtains “PRIME” status from the European Medicines Agency for glenzocimab in the treatment of stroke

Paris, France, July 21, 2022 – 7:00 PM CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.

Read More »
2022-07-21